

# CORE INNOVATION

LANDMARKS 2019



# **TAKING INNOVATION TO THE HIGHEST LEVEL**

---

**As the leading Cancer Centre in Europe, Gustave Roussy is ranked among the ten world leaders in oncology research and patient care.**

The Institute treats patients with every type of cancer at any age and is expert in the treatment of rare and complex tumours.

The Gustave Roussy units share the values of regard for the individual, creativity, daring inventiveness and collaboration. They respond to a continuing challenge: to deliver to patients the fruits of the most recent advances.

Gustave Roussy embarked in 2018 on an investment plan on an unprecedented scale which aims to continue acquiring the latest equipment and to increase the number of patients we can treat, so that we maintain our innovation at the highest level and deliver it to the greatest number. Gustave Roussy will be investing a total of 250 M€ to modernise the Institute over the period up to 2024. It is at the heart of the plans for the

overall re-development of the “Campus Grand Parc”. In 2021, Gustave Roussy will open a new building of more than 11,000 m<sup>2</sup> connected to the old one. It will incorporate a Day Hospital and a Wellness Centre.

Our ambition is immense: extending the frontiers of science, continuously reinventing methods of treatment of patients and exploring every source of innovation.

Our doctors and researchers devote their energies and their skills to this great challenge: to speed up progress in order to expand the limits of knowledge and offer patients continuing improvements in the specificity of their treatment. And to raise the hope of curing cancer in the 21<sup>st</sup> century.

# CONDUCTING DARING RESEARCH

**Gustave Roussy is always in the vanguard of progress.** It brings together the best workers in fundamental, clinical and translational research. Very close collaboration between research scientists and doctors means that patients get access in the shortest possible time to the very latest developments in treatment.

Through the impact of its scientific articles and the presence of its researchers at international conferences, Gustave Roussy proves the effectiveness of its model as an integrated centre for research and clinical practice. The activities of the Institute's research units are concentrated on personalised medicine, immunotherapy, DNA repair and artificial intelligence.



## A GUSTAVE ROUSSY UNIVERSITY HOSPITAL INSTITUTE OF PRECISION MEDICINE

In 2018, the Prism project at Gustave Roussy was designated as a University Hospital Institute. This is a collaboration between Inserm, CentraleSupélec, the Paris-Sud University, Unicancer and the ARC (Association for Cancer Research) Foundation. This second generation oncological precision medicine institute is coordinated by Professor Fabrice André and its goal is to model cancer at the individual level in order to select the most appropriate medication for each patient. Prism will be conducting large-scale clinical studies and developing techniques for molecular and data analysis.

**74 M€**  
dedicated to research



**304**  
international publications  
with an impact factor > 10  
(excluding conferences)

**72**  
trials sponsored  
by Gustave Roussy  
of which 9 in Precision  
Medicine Programme

**27 %**  
of the patients treated  
in 2018 were involved  
in a clinical research



**241**  
clinical trials in  
immunotherapy since 2013,  
of which 64 in 2018

**518**  
patients included  
in phases I and I/II trials

**4,895**  
Gustave Roussy patients  
have participated in the  
Precision Medicine  
Programme since 2011

**469**  
clinical trials in 2018

# OFFERING INNOVATIVE CARE

---

**Gustave Roussy is committed to being the engine of rapid progress in oncology, whether in terms of therapy or care pathways.** Employing novel methods of caring for individual patients in the least invasive way possible and by ensuring that this takes place in the safest way, the Institute is giving cancer patients high quality care from the time of diagnosis on through their treatment.

As a university hospital institute, Gustave Roussy disposes of a full therapeutic arsenal for its patients: immunotherapy, chemotherapy, radiotherapy, interventional radiology, DNA sequencing, oncological and reparative surgery, etc. Its infrastructure functions at the highest level: surgical robots, a day surgery department, radiosurgery, brachytherapy, robotic chemotherapy drug preparation systems, genomics, etc.

Gustave Roussy is positioned today in the first European rank for early trials with a dedicated Drug Development Department (Ditep) to facilitate patient access to new medicines. Whereas the mean numbers of cancer patients recruited to a clinical trial in France lie between 4 and 10%, the figure for Gustave Roussy patients participating in such research is 27%.

**223,500**  
medical consultations

**53,000**  
ambulatory stays  
(excluding radiotherapy)

**19,400**  
hospital stays

**4,052**  
patients treated  
by radiotherapy and  
62,300 sessions

**655**  
patients treated  
by tomotherapy  
and 16,214 sessions

**6,093**  
patients treated  
with chemotherapy

**5,850**  
new patients admitted  
to standard wards

**269**  
stem cell transplantations  
of which 62 in paediatrics

**2,408**  
patients treated  
by interventional radiology

**92 %**  
bed occupancy rate



# PASSING ON KNOWLEDGE

---

**Gustave Roussy fulfils a mission to teach and pass on its oncological expertise to train doctors, research scientists, nurses, students and all health professional looking after cancer patients.** These high grade educational programmes are delivered by recognised experts, actively engaged in making advances in the field and they facilitate the rapid spread of new therapies and constantly developing knowledge.

The École des sciences du cancer was set up in 2012 by Gustave Roussy and Paris-Sud University. It is the only such establishment in France. Its high level teaching body educates students for the new types of posts in oncology with courses leading to degrees and other qualifications.

The École has developed a model of teaching focused on pictorial and digital presentations and interaction with the student: a website for digital forms of teaching complements the École's teaching tools.

In addition, the École doctorale en cancérologie, the only doctoral school in France with the single theme of oncology, comprises 85 research units and welcomes 55 new doctoral students per year.

**551**

practitioners teaching in the  
École des sciences du cancer,  
204 of them from Gustave Roussy



**26**

university teachers

**26**

university  
diplomas

&

**2**

masters

×

**40**

scientific seminars  
and master classes

**10,000**

registered students on the digital  
learning platform of the  
École des sciences du cancer

×

**245**

doctoral students  
in the École doctorale  
de cancérologie

**200,000**

articles and e-books downloaded,  
from the stock of 3,559 e-books  
and 600 journals

# MOBILISING GIVING

---

**The Institute is a “private establishment of collective benefit” and, just like the Gustave Roussy Research Foundation, is authorised to receive donations and bequests.** Public generosity forms an essential support for our research units and care departments, acting as a real stimulus to progress by giving Gustave Roussy staff the means to advance in the fight against cancer in fundamental, clinical and translational research and by improving patients’ quality of life.

In 2017, Gustave Roussy launched two major fund-raising campaigns: “Curing cancer in the 21<sup>st</sup> century” and “Curing childhood cancer in the 21<sup>st</sup> century”, which aim to collect fifty and ten million euros respectively by 2020.

The “Curing cancer in the 21<sup>st</sup> century” campaign fund reached 32 M€ in 2018 and the campaign for research in paediatric oncology continues to do well with overall funds of 5.5 M€.

An increase of 4% in funds raised in a sector which is doing badly elsewhere (50% mean reduction for some foundations and charitable associations) shows that the French feel concern for medical research, especially in cancer. They are choosing to donate to Gustave Roussy as the best way to achieve a cure for cancer.

In 2018, Gustave Roussy and its Foundation benefitted from the renewal of accreditation for “Donate in confidence” which certifies that donations are handled transparently and used properly.

×

**12 M€**  
collected in the form  
of bequests and gifts, i.e. 34%  
of the money raised in 2018

**35 M€**  
of donations and bequests  
collected by Gustave Roussy  
and its Foundation, compared  
with 33.8 M€ in 2017

**4 %**  
increase in giving  
compared with 2017

More than  
**1,200**  
active research sponsors

Major  
philanthropists:  
**55 %**  
of the total of donations  
to Gustave Roussy  
and its Foundation in 2018

**98,000**  
donations

×

# GUSTAVE ROUSSY AT A GLANCE

427

beds

&

124

places in day  
hospital

×

48,000

patients seen in in-clinic  
of whom 11,000 had  
their first appointment



53,000

ambulatory stays  
(excluding radiotherapy)

27 %

of the patients treated  
in 2018 were involved  
in a clinical research

19,400

hospital stays in full admission

396,1 M€

overall budget



64

international  
publications  
with an IF >30

3,100

employees



3,300

students and practitioners trained,  
and 6,700 trained on line

1200  
nursing  
staff

×

950  
research  
staff

34

research teams and  
10 research units

520

medical staff  
and 446 full-time  
equivalent

×

74

patent families

“**W**e are putting **Gustave Roussy**  
*in marching order to pursue its  
mission by anticipating today how  
patients will be cared for tomorrow.*”

---

**Professor Alexander Eggermont**  
**General Director**



[www.gustaveroussy.fr](http://www.gustaveroussy.fr)

114, rue Édouard-Vaillant  
94805 Villejuif Cedex - France

**GUSTAVE/  
ROUSSY**  
CANCER CAMPUS  
GRAND PARIS

A graphic element consisting of several colored diagonal lines (orange, green, pink) extending from the bottom right of the text.